THERAPY DOSSIER · th-6979d539ba18

Potassium bisperoxo(picolinato)vanadium, bpV(pic)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22253859 ↗2012Reported benefit

Systemic bisperoxovanadium activates Akt/mTOR, reduces autophagy, and enhances recovery following cervical spinal cord injury.

RatSpinal cord injuryContusionSprague-Dawleyfemalen = 40 rats in total; bpV(pic) n=14, vehicle n=12, sham n=14, w…intraperitoneal400 micrograms/kgimmediately after surgery and injury

Model: moderate unilateral cervical (C5) contusive spinal cord injury with dura intact using the NYU MASCIS impactor (2.5 mm tip, 10 g weight, 12.5 mm height)

bpV(pic) reduced lesion volume and cavitation, spared motor neurons and grey matter vasculature and improved forelimb function at 6 weeks, with restored p-Akt, increased p-S6 and a lower LC3 II/LC3 I ratio at 1 day.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…